Healthcare Industry News:  Cardinal Health 

Diagnostics Distribution

 News Release - February 14, 2007

Abaxis Announces Distribution Agreement With Cardinal Health

Piccolo Xpress chemistry analyzer and medical reagent discs to be available for distribution from Cardinal Health

UNION CITY, Calif., Feb. 14 (HSMN NewsFeed) -- Abaxis, Inc. (Nasdaq: ABAX ), a medical products company manufacturing point-of-care blood analysis systems, announced today that it has entered into a distribution agreement with Cardinal Health to sell and distribute the Piccolo Xpress blood chemistry analyzer and medical reagent discs.

Clint Severson, chairman and chief executive officer of Abaxis commented, "We are pleased to make the Piccolo Xpress product available to healthcare providers in the United States through Cardinal Health. We feel this relationship will expand our product reach to customers in the ambulatory market."

"This relationship will provide us the opportunity to expand market coverage within the point-of-care product segment," said Chris Bernard, vice president of sales and marketing for Abaxis. "It will also provide us the opportunity to improve our understanding of the ambulatory market and further extend the reach of our sales force."

About Abaxis

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 6.9 kilogram (15 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 14 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may", "believes", "projects", "expects", or "anticipates", and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to, risks and uncertainties related to fluctuations in the Company's share price, the market acceptance of the Company's products and the continuing development of its products, required United States Food and Drug Administration ("FDA") clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with entering the human diagnostic market on a larger scale, risks related to the protection of the Company's intellectual property or claims of infringement of intellectual property asserted by third parties, risks involved in carrying of inventory, risks associated with the ability to attract, train and retain competent sales personnel, general market conditions, competition and other risks detailed from time to time in Abaxis' periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statement was made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.


Source: Abaxis

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.